Literature DB >> 17983372

Health-related quality of life in allergic rhinitis: comparing the short form ESPRINT-15 and MiniRQLQ questionnaires.

A Valero1, J Alonso, I Antépara, E Baró, C Colás, A del Cuvillo, M Ferrer, M Herdman, E Marti-Guadaño, L Monclús, A M Navarro-Pulido, J Sastre, I Izquierdo, J Mullol.   

Abstract

BACKGROUND: We compared the psychometric properties of the ESPRINT-15, the short form of a new Spanish instrument to measure health-related quality of life in allergic rhinitis (AR) patients, with those of the Mini-Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ).
METHODS: The questionnaires were compared in Spanish patients with intermittent allergic rhinitis (IAR) or persistent AR in a prospective, observational study. Floor and ceiling effects, internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient; ICC), convergent and known groups validity, and sensitivity to change (standardized response means; SRMs) were compared.
RESULTS: In terms of content, while the MiniRQLQ has a dimension covering practical problems and places more emphasis on symptoms, the ESPRINT-15 has two dimensions (Sleep and Psychological impact) which are not included in the MiniRQLQ. In the validation study, 400 patients were included and 59% of the sample had persistent AR. There were no significant floor or ceiling effects on any dimension on either questionnaire. Cronbach's alpha values for the ESPRINT-15 and MiniRQLQ overall scores were 0.92 and 0.90, respectively. In 48 clinically stable patients, ICCs were 0.80 and 0.77, respectively. Both instruments discriminated between patients with IAR and persistent AR. Correlations with symptom scores and generic measures were moderate to strong. SRMs for overall scores and individual dimensions on the two questionnaires in the 197 patients reporting a change in health status ranged from 0.7 to 1.3.
CONCLUSIONS: Both questionnaires performed well in psychometric terms. The ESPRINT-15 is particularly recommended for use in Spanish-speaking populations.

Entities:  

Mesh:

Year:  2007        PMID: 17983372     DOI: 10.1111/j.1398-9995.2007.01552.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

Review 1.  Comparative analysis of allergic rhinitis in children and adults.

Authors:  Adriana Izquierdo-Domínguez; Antonio L Valero; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

Review 2.  Impact of sleep as a specific marker of quality of life in allergic rhinitis.

Authors:  Vanesa González-Núñez; Antonio Luís Valero; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

3.  Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis.

Authors:  Antonio Valero; Iñaki Izquierdo; Marek L Kowalski; Glenis K Scadding; Jean Bousquet; Joaquim Mullol
Journal:  Allergy Asthma Clin Immunol       Date:  2020-04-23       Impact factor: 3.406

4.  Classic test and generalizability theories are both useful for cross-cultural adaptation of an allergic rhinitis health-related quality of life questionnaire.

Authors:  Juan José Yepes-Nuñez; Edison Morales Cardenas; Carolina Gómez-García; Madelen Manco Sepúlveda; Lina Marcela Martínez; Antonio Valero; Meghan M McConnell
Journal:  World Allergy Organ J       Date:  2021-11-29       Impact factor: 4.084

5.  A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study).

Authors:  Pedro Ojeda; Núria Piqué; Alicia Alonso; Julio Delgado; Francisco Feo; Juan Manuel Igea; Ana Navarro; José María Olaguibel; Javier Subiza; Carles Nieto; Morgan Andersson
Journal:  Allergy Asthma Clin Immunol       Date:  2013-08-27       Impact factor: 3.406

6.  Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy.

Authors:  A Roger; E Arcalá Campillo; M C Torres; C Millan; I Jáuregui; E Mohedano; S Liñan; P Verdu; N Rubira; M Santaolalla; P González; A Orovitg; E Villarrubia
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-11       Impact factor: 3.406

7.  Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort.

Authors:  R Muñoz-Cano; P Ribó; G Araujo; E Giralt; J Sanchez-Lopez; A Valero
Journal:  Clin Transl Allergy       Date:  2018-07-09       Impact factor: 5.871

8.  Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis.

Authors:  Joaquim Mullol; Iñaki Izquierdo; Kimihiro Okubo; Giorgio Walter Canonica; Jean Bousquet; Antonio Valero
Journal:  Clin Transl Allergy       Date:  2019-10-09       Impact factor: 5.871

9.  Effect of Silver Nitrate Cauterisation of Nasal Mucosa on Quality-of-Life and Histology in Patients with Intractable Chronic Rhinitis.

Authors:  Nedha Joy; Jenny Jacob; Regi Kurien; Lalee Varghese; Suganthy Rabi; V Rupa
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.